Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (968)	3/7/1998 9:54:00 AM
From: louis mason	Read Replies (2) \| Respond to of 3576

Marty, I'm glad that you feel that the bottom line here is finding an additional treatment against cancer. This underscores my feeling all along that it's the science that matters with respect to telomerase, not the confused claims of who owns the rights to the ideas. Lets face it, the telomerase assay was in the publications years before GERN thought to patent the ideas. This issue with Bristol-Myers just indicates that anybody can do this research if they want to get involved. All GERN did was propose the PCR amplification method which is totally unnecessary for a screening program. As for Bristol-Myers paying any royalties- I doubt it. GERN's lawyers probably already contacted U. of Texas at Austin on the 5th and demanded that they retract the news release- and the U. of Texas officials told them to 'take-a-hike.' Remember that the collaborations that Geron has are with UT Southwestern in Dallas. The "big" state school of Texas is U.of T. in Austin. Marty, I know you think that I'm somehow against GERN, but that's not true at all. I just think that someone out here needs to stand up against their megalomaniacal claims that they own telomerase. Personally, I hope GERN succeeds in their efforts through good science & not litigation and obnoxious PR campaigns. Good luck, l mason